Ablynx is looking for new partners to take its rheumatoid arthritis drug vobarilizumab into phase 3 development, after AbbVie turned down an option to license the drug. AbbVie has already paid the ...

MoonLake Immunotherapeutics starts Phase 3 IZAR program of the Nanobody® sonelokimab in patients with active psoriatic arthritis Two trials for active psoriatic arthritis (PsA) with one focusing on ...

Sanofi has leapt in to buy Ablynx for €3.9 billion ($4.85bn) outbidding an offer from Novo Nordisk which the European biotech had declined two weeks ago. For Sanofi, the acquisition comes hot on ...

Ablynx, Chimerix, Karyopharm Therapeutics, Schering-Plough, ViiV Healthcare, the American Physician Institute, DiaSorin, the Association for the Advancement of Blood & Biotherapies, Ortho Clinical ...

PG has served as an advisor or speaker or has received research support from 3NT, Ablynx, ALK, ArgenX, AstraZeneca, Bekaert Textiles, Genentech, GSK, Hall Allergy, Medtronic, Novartis, Regeneron ...

Prior to BMS, she held positions of leadership at pharmaceutical companies Janssen and Merck, and served as CSO at biotech firms Jounce Therapeutics and Ablynx NV. She obtained a Doctor of ...

MoonLake Immunotherapeutics Reports Third Quarter 2024 Financial Results and Provides a Business Update Ended the third quarter with $493.9 million in cash, cash equivalents and short-term marketable ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion sales in 2023, it shows no signs ...

Welcome to the Q3 2024 conference call for investors and analysts. As usual, you can find the slides on sanofi.com. Please turn to Slide number 3. Here we have the usual forward-looking statements ...

Read More: Earn up to $845 cash back this year just by changing how you pay at Costco! Learn more here. Thomas Kudsk Larsen-- ...

21 RFL Rafael Holdings, Inc. Class B 0.00% ...

DiveWire guarantees visibility for your news announcements through instant distribution to BioPharma Dive’s audience and its 153,500 newsletter subscribers for 21 days.